Valuation: Akari Therapeutics, Plc

Market Cap 19.61M 17.6M 16.25M 14.73M 27.54M 1.86B 27.88M 195M 77.37M 976M 73.6M 72.02M 3.1B P/E 2026 *
-1.61x
P/E 2027 * -7.36x
Enterprise Value 19.61M 17.6M 16.25M 14.73M 27.54M 1.86B 27.88M 195M 77.37M 976M 73.6M 72.02M 3.1B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.9%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Akari Therapeutics, Plc

1 day+12.45%
1 week-7.64%
Current month-7.74%
1 month-12.05%
3 months+1.42%
6 months+53.21%
Current year-25.78%
1 week 7.58
Extreme 7.58
9.12
1 month 7
Extreme 7
10.75
Current year 3.02
Extreme 3.015
29.32
1 year 3.02
Extreme 3.015
33.6
3 years 3.02
Extreme 3.015
176
5 years 3.02
Extreme 3.015
1,384
10 years 3.02
Extreme 3.015
17,759.84
Manager TitleAgeSince
Chief Executive Officer 52 2025-04-20
Director of Finance/CFO 48 2025-10-21
Chief Tech/Sci/R&D Officer 72 2022-11-07
Director TitleAgeSince
Chairman 81 2015-08-31
Director/Board Member 56 2023-11-28
Director/Board Member 58 2024-09-16
Date Insider Type Main position Quantity % Market Cap. Importance
10/14/26 Exercice

Director

20,104 0.8798%
10/14/26 Exercice

Director

7,732 0.3384%
10/14/26 Exercice

Chief Executive Officer

54,132 2.3688%
Change 5-day change 1-year change 3-year change Capi.($)
+12.45%-7.64%-73.00%-94.04% 19.61M
+0.22%-0.14%+55.12%+128.82% 1,143B
+0.91%+3.61%+41.21%+84.57% 647B
-0.12%-0.93%+25.59%+106.14% 506B
-1.53%+0.56%+50.98%+63.37% 384B
+0.86%-4.37%+61.16%+37.93% 350B
-0.17%+1.58%+30.35%+52.29% 293B
-0.95%+0.94%+2.63%+24.60% 265B
+0.75%+2.05%+53.85%+71.25% 242B
+0.25%+1.64%+32.05%+107.62% 197B
Average +0.82%-0.00%+27.99%+58.25% 402.76B
Weighted average by Cap. -0.63%+0.71%+42.84%+87.79%

Financials

2026 *2027 *
Net sales - -
Net income -26.85M -24.1M -22.25M -20.18M -37.72M -2.55B -38.18M -267M -106M -1.34B -101M -98.64M -4.24B -20.89M -18.75M -17.31M -15.7M -29.35M -1.98B -29.71M -208M -82.44M -1.04B -78.43M -76.75M -3.3B
Net Debt - -
Projected Income Statement - Annual - Akari Therapeutics, Plc
Logo Akari Therapeutics, Plc
Akari Therapeutics, Plc is a biotechnology company developing precision bifunctional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. It is pursuing research on two additional novel payloads, such as PH5 and PH6. It also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.
Employees
6
Date Price Change Volume
26-10-27 US$8.580 +12.45% 38,456
26-10-26 US$7.630 -7.23% 67,835
26-10-23 US$8.225 +1.54% 14,399
26-10-22 US$8.100 -7.53% 20,885
26-10-21 US$8.760 -5.71% 30,597
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Akari Therapeutics, Plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.580USD
Average target price
25.50USD
Spread / Average Target
+197.20%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Akari Therapeutics, Plc
  1. Stock Market
  2. Stocks
  3. AKTX Stock